Co-payment is based on the recommended maximum dose.

Cost-sharing for certain medications will be based on the recommended maximum dose according to the drug's marketing authorization in Iceland. This arrangement will take effect on January 1, 2026. Assessment of drug use is based on the invoices sent to Iceland Health. If an individual's total use exceeds the reference dose, the cost-sharing is discontinued, and the individual then pays the full cost.

The change is in accordance with Article 6 of Regulation No. 1143/2019 on the contribution of Iceland Health to the cost of medicines, which states, among other things:

"Iceland Health is authorized to limit the contribution of Iceland Health to an individual's medication costs, which has been approved pursuant to subsection 2, paragraph 2 of Article 66 of the Pharmaceuticals Act, to a specific dosage that exceeds the recommended maximum dosage according to the marketing authorization of the medicine in this country."

[03.12.25 This news has been updated]